Biosimilars

Explore approved biosimilar medicines

# Medicine Status Active Substance Therapeutic Area Developer Published Date
21 Kanjinti Authorised trastuzumab Stomach Neoplasms;Breast Neoplasms Amgen Europe B.V. 17-08-2018
22 Afiveg Authorised aflibercept Wet Macular Degeneration;Macular Edema;Diabetes Complications;Retinal Vein Occlusion;Choroidal Neovascularization STADA Arzneimittel AG 20-06-2025
23 Uzpruvo Authorised ustekinumab Psoriasis;Arthritis, Psoriatic;Crohn Disease;Colitis, Ulcerative Stada Arzneimittel AG 10-11-2023
24 Usgena Authorised ustekinumab Crohn Disease;Psoriasis;Arthritis, Psoriatic;Colitis, Ulcerative Stada Arzneimittel AG 19-09-2025
25 Dazublys Authorised trastuzumab Breast Neoplasms;Stomach Neoplasms CuraTeQ Biologics s.r.o 12-08-2025
26 Ondibta Authorised insulin glargine Diabetes Mellitus Gan & Lee Pharmaceuticals Europe GmbH 14-11-2025
27 Rexatilux Opinion ranibizumab Wet Macular Degeneration Intas Third Party Sales 2005 S.L. 24-04-2026
28 Vysribli (previously Denosumab Intas) Authorised denosumab Bone Resorption;Osteoporosis;Osteoporosis, Postmenopausal Intas Third Party Sales 2005 S.L. 19-09-2025
29 Terrosa Authorised teriparatide Osteoporosis Gedeon Richter Plc. 23-02-2018
30 Amgevita Authorised adalimumab Arthritis, Psoriatic;Colitis, Ulcerative;Arthritis, Juvenile Rheumatoid;Spondylitis, Ankylosing;Psoriasis;Crohn Disease;Arthritis, Rheumatoid Amgen Europe B.V. 20-07-2018

Get in Touch

Ready to transform your strategic intelligence? Let's talk

Subscribe to Our Newsletter

Get latest pharmaceutical insights, blogs, and strategic updates directly in your inbox.